NHU(SZ:002001)2022-11-11 05:52Group 1: Financial Performance - In the first half of 2022, the company achieved operating revenue of 821,503.93 million yuan, an increase of 11.92% compared to the same period last year [1] - Total profit amounted to 262,396.23 million yuan, a decrease of 7.28% year-on-year [1] - Net profit attributable to shareholders was 221,387.74 million yuan, down 8.78% from the previous year [1] Group 2: Business Segment Performance - The nutrition segment saw a revenue increase of 4.81%, driven by stable sales of methionine [2] - The flavor and fragrance segment experienced a revenue growth of 31.17%, while the new materials segment grew by 32.06% [2] - The new materials segment generated 55,251.44 million yuan, accounting for 6.73% of total revenue, with a year-on-year growth of 32.06% [3] Group 3: Project Development - Major projects are progressing smoothly, with the methionine phase II project of 250,000 tons/year expected to be operational by June 2023 [2] - The company is advancing its 5,000 tons/year vitamin B6 and 3,000 tons/year vitamin B12 production, along with a 30,000 tons/year taurine project [2] - The new materials segment's PPS phase III project is in trial production, while the adiponitrile project is in the pilot testing phase [2] Group 4: Strategic Focus and Future Plans - The company emphasizes innovation-driven development, focusing on fine chemicals and functional chemical products across various platforms [2] - Plans to diversify product offerings in the flavor and fragrance segment, moving towards a more integrated and collaborative product structure [4] - The company aims to enhance its competitive edge through continuous improvement in product quality and technology [2]